Merck Reports Five-Year KEYNOTE-426 Data for Keytruda Plus Inlyta in Renal Cell Carcinoma

Merck today presented five-year overall survival data from the Phase 3 KEYNOTE-426 trial evaluating Keytruda (pembrolizumab) plus axitinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma. The data showed that 38% of patients in the Keytruda plus axitinib arm were alive at five years compared to 33% in the sunitinib arm.